造血细胞移植后迟发性巨细胞病毒病:新型移植技术的意义
该回顾性研究分析了2001-2017年抢先治疗队列与2018-2021年来特莫韦队列中CMV血清阳性第100天存活者的迟发性CMV病,发现第100天存活者中迟发性CMV病累积发生率为7.2%,两队列无差异,移植后环磷酰胺等与胃肠道CMV病风险增加相关,迟发性CMV病与移植后2年内死亡独立相关。
要点
- 第100天存活者迟发性CMV病累积发生率为7.2%(95%CI 6.2-8.3),抢先治疗队列与来特莫韦队列无差异。
- 移植后环磷酰胺与胃肠道CMV病风险增加相关,第100天后≥1 mg/kg糖皮质激素治疗等亦为危险因素。
- 迟发性CMV病多发生于持续低水平未治疗病毒血症背景下,与移植后2年内死亡独立相关。
核心结论
- 迟发性CMV病在当前时代仍持续发生,需要改进的预防策略。
研究设计与样本
- 回顾性研究,纳入2001-2017年抢先治疗队列与2018-2021年来特莫韦队列中CMV血清阳性且第100天存活者的异基因造血细胞移植受者。
主要发现
- 2469例第100天存活者中发生203例次迟发性CMV病,首次迟发性CMV病估计累积发生率为7.2%(95%CI 6.2-8.3),抢先治疗队列为7.4%(95%CI 6.4-8.6),来特莫韦队列为5.4%(95%CI 3.2-8.3),两者无差异。
- 37例患者(1.5%)发生第二次CMV病。
- 多变量Cox回归模型中,移植后环磷酰胺与胃肠道CMV病风险增加相关。
- 第100天前检测到的CMV病毒血症或疾病、第100天后剂量≥1 mg/kg的糖皮质激素治疗、急性和慢性移植物抗宿主病、淋巴细胞减少、HLA不相合相关供者状态也与迟发性CMV病相关。
- HLA不相合供者状态和迟发性使用糖皮质激素(≥1 mg/kg)是迟发性CMV病复发的危险因素;迟发性CMV病与移植后2年内死亡独立相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preemptive therapy (PET) and letermovir prophylaxis are effective in preventing cytomegalovirus (CMV) disease within the first 100 days after allogeneic hematopoietic cell transplantation (HCT) but are associated with late-onset CMV disease. We retrospectively examined the clinical manifestations, risk factors, prevention algorithm, and outcome of late CMV disease in CMV seropositive day 100 survivors transplanted between 2001-2017 (PET cohort) and 2018-2021 (letermovir cohort). There were 203 episodes of late CMV disease among 2469 day 100 survivors, and the estimated cumulative incidence of first late CMV disease was 7.2% (95% confidence interval [CI], 6.2-8.3) with no difference between the PET (7.4%; 95% CI, 6.4-8.6) and the letermovir group (5.4%; 95% CI, 3.2-8.3). Thirty-seven patients (1.5%) had a second episode of CMV disease. In multivariable Cox regression models, posttransplant cyclophosphamide was associated with an increased risk of gastrointestinal CMV disease. CMV viremia or disease detected before day 100, corticosteroid treatment after day 100 at dose ≥1 mg/kg, acute and chronic graft-versus-host disease, lymphopenia, HLA-mismatched related donor status, were also associated with late CMV disease. HLA-mismatched donor status and late use of corticosteroids (≥1 mg/kg) were risk factors for late CMV disease recurrence. Late CMV disease occurred most frequently in a setting of prolonged low-level untreated viremia and was independently associated with death by 2 years after HCT. In summary, late CMV disease continues to occur in the present era. Improved prevention strategies for late CMV disease are needed.
引用
- Sadowska-Klasa A, Özkök S, Xie H, et al. Late cytomegalovirus disease after hematopoietic cell transplantation: significance of novel transplantation techniques. Blood Adv. 2024. PMID: 38537062. doi:10.1182/bloodadvances.2023012175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。